

RESEARCH

Open Access



Neuroimaging and machine learning for studying the pathways from mild cognitive impairment to alzheimer's disease: a systematic review

Maryam Ahmadzadeh¹, Gregory J. Christie¹, Theodore D. Cosco^{2,3}, Ali Arab⁴, Mehrdad Mansouri⁴, Kevin R. Wagner², Steve DiPaola^{1*} and Sylvain Moreno¹

Abstract

Background This systematic review synthesizes the most recent neuroimaging procedures and machine learning approaches for the prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia.

Methods We systematically searched PubMed, SCOPUS, and Web of Science databases following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) systematic review guidelines.

Results Our search returned 2572 articles, 56 of which met the criteria for inclusion in the final selection. The multimodality framework and deep learning techniques showed potential for predicting the conversion of MCI to AD dementia.

Conclusion Findings of this systematic review identified that the possibility of using neuroimaging data processed by advanced learning algorithms is promising for the prediction of AD progression. We also provided a detailed description of the challenges that researchers are faced along with future research directions. The protocol has been registered in the International Prospective Register of Systematic Reviews– CRD42019133402 and published in the Systematic Reviews journal.

Keywords Systematic review, Alzheimer, Mild cognitive impairment, Prediction, Neuroimaging, Machine learning

*Correspondence:

Steve DiPaola
sdipaola@sfu.ca

¹School of Interactive Arts and Technology, Simon Fraser University, 250 – 13450 102 Ave, Surrey, BC, Canada

²Gerontology Research Center, Simon Fraser University, Vancouver, BC, Canada

³Oxford Institute of Population Ageing, University of Oxford, Oxford, UK

⁴Department of Computing Science, Simon Fraser University, Burnaby, BC, Canada



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Background

Alzheimer's disease dementia (AD) is a slowly evolving neurodegenerative disorder that can begin 20 years or more before clinical diagnosis [1]. Through the progression of Alzheimer's disease, multiple brain neurons and their connections are damaged or destroyed which affects an individual's basic daily life functions such as walking, talking or swallowing [2]. The number of deaths due to AD has increased by 145% from 2000 to 2017 and is projected to increase further as the number of older adults (aged 65+) increases throughout the world [2]. While the risk of death due to Alzheimer's disease raises with aging, currently, a disease-modifying/blocking treatment for severe AD is not available [3].

The early stages of AD comprise a symptomatic prodromal phase of dementia referred to as mild cognitive impairment (MCI) [4]. Ideally, treatments for AD would be initiated in this MCI stage before the subsequent accumulation of irreversible neurological damage [3]. However, not all individuals in this MCI stage will progress to AD, and a large number of research studies have attempted to develop models capable of identifying those at high risk of progressing from MCI to AD dementia from those at low risk [4–6]. If successful, this would help researchers target individuals who would most benefit from prospective therapies with early interventions and clinical trials.

In the last decade, with advances in the analysis of neuroimaging data, many studies have shown the potential of these modalities in facilitating the detection of AD in its early stages as well as the prediction of clinical progression to AD [7–12]. In this regard, the present review includes data acquired using positron emission tomography (PET), structural magnetic resonance imaging (MRI), functional MRI, Single Photon Emission Computed Tomography (SPECT), and electroencephalography (EEG) modalities, which are common techniques for the acquisition of functional and anatomical brain data. Given that each of these modalities has certain advantages and limitations, some researchers have turned to use combinations of different modalities to obtain a more comprehensive set of neurological data; these studies are also included in the present review. However, due to the high complexity of the brain function and structure, there are still unresolved challenges regarding the efficient techniques to integrate multiple measures and modalities that are associated with the transition to AD dementia.

Several data analysis approaches including machine learning and deep learning algorithms have been developed to automatically analyze and quantify brain function, structure, morphology, and connectivity to identify individuals at risk of converting from MCI to AD [13–15]. Recent years have seen considerable growth in the number of machine learning (ML) algorithms (i.e.,

support vector machine, random forest, ensemble multiple kernel learning, K-nearest neighbor) that have been developed for this, using high-dimensional clinical and biomarker data [5, 16, 17]. In particular, ML algorithms can learn fine and complex patterns of change that occur across the neuroimaging modalities during the process of progression from MCI to AD dementia. However, the effective clinical translation of these approaches still requires a generalizable model that can be applied in real-life settings with the general public.

Consequently, the overarching objective of the present work is to provide a systematic review of recently published studies focused on the prediction of conversion from MCI to AD dementia using neuroimaging modalities and machine learning approaches. Our review will synthesize two main areas of active research: (i) an exploration of the most recent neuroimaging modalities used to predict MCI individuals who progress to AD, and (ii) a systematic discussion of machine learning techniques applied to identify the changes of factors contributing to the transition from MCI to AD dementia.

Methods

Study protocol

The methods of this systematic review have been conducted in accordance with the PRISMA guidelines for systematic reviews [18]. The protocol has been registered in the International Prospective Register of Systematic Reviews—CRD42019133402 and published in the Systematic Reviews journal [19].

“Systematic review protocol is like a roadmap that provides in advance information on the objectives, hypothesis, and methods of reviewing the published studies. This assists in outlining the whole process of systematic review in a transparent way. However, in the review discussion, the results of the study are evaluated, interpreted, and explained. The relationships between the findings and literature review, and arguments in support of the conclusions are discussed. Furthermore, limitations of the study and recommendations regarding the future pathway are provided.”

Search strategy

A systematic search was performed across three electronic databases: PubMed, Web of Science, and Scopus. Because the present review paper focuses on a cutting-edge research topic that is developing quickly, we restricted our review to a recent window of time from January 1st, 2017 to March 1st, 2019. The search strategy for PubMed/MEDLINE database is presented in Additional file 1. The search string was adapted to the search mechanisms of each of the selected databases. We further hand-searched the reference lists of included articles to

identify additional studies to complement the electronic searches.

Study selection

Two authors (MA and KRW) independently screened the titles and abstracts of all articles identified from the initial search according to the inclusion/exclusion criteria. If the relevance of an article was unclear from its title and abstract, both reviewers examined the full text of the paper in detail. Conflicts between the two authors were resolved through discussion, and in case of disagreement, a third reviewer (TDC) was consulted to make the final decision. For the present review, the following inclusion criteria were used: (1) all studies had to address research on Alzheimer's disease and MCI; (2) all studies had to have focused on the prediction of conversion from MCI to AD; (3) all studies had to describe the results in a way that allowed us to extract the accuracy, sensitivity and/or specificity of the method at predicting conversion to AD, for comparison purposes; (4) we included those studies that described their methods in sufficient detail to enable replication; (5) we included all studies that used at least one type of neuroimaging modality in their research; and (6) all studies had to be published between January 1st, 2017 and March 1st, 2019. The current review paper has focused on a cutting-edge research topic that is fast paced; therefore, we limited the search to examine only recent studies. Studies with any of the following characteristics were excluded: (1) articles addressing research on other types of dementia such as Frontotemporal dementia, Lewy body dementia, Vascular dementia, Huntington's disease, and Parkinson's disease and mixed dementia; and (2) ineligible or non-peer-reviewed studies such as conference proceedings, editorial, secondary data analyses, review articles, and book reviews. We did not impose language restrictions on the search and translated articles when necessary.

Data extraction

Using a predefined standardized template to extract data from the included studies, we investigated research on the prediction of progression from MCI to AD dementia using biomedical image processing with machine learning techniques. Thus, we explored various modalities that have been used in the selected studies as well as data analysis techniques in the early prediction of AD dementia. In this context, the two aforementioned reviewers extracted the following data: (1) author(s); (2) year of publication; (3) source of data; (4) follow-up period (conversion period); (5) sample size (number of participants with MCI, stable MCI, and progressive MCI); (7) modalities; (8) neuroimaging feature; (9) data analysis techniques and (10) performance of results including accuracy, sensitivity, specificity. Additionally, If the

information in a study were not unclear or missing, we contacted the authors for clarification.

Data synthesis

In instances where meta-analysis was not possible, we aimed to explore heterogeneity descriptively using structured narratives and summary tables. Therefore, a narrative synthesis method was used to describe the results of the identified studies. In this context, we provided a descriptive summary focused on the investigation of neuroimaging modalities, features, data resources and data analysis techniques, and performances in terms of accuracy, sensitivity, and specificity. Data synthesis could help us to identify gaps in the evidence, areas of strength and fields in need of improvement related to methodological development and biomarkers identification to achieve the main goal of prediction of progression from MCI to AD.

Results

Study selection

The initial search of three databases identified 2556 articles. An additional 16 articles were identified by hand-searching the articles' references and other sources. After eliminating duplicate results, this was reduced to 1431 articles for prospective inclusion. Next, the titles and abstracts of these articles were screened based on the exclusion/inclusion criteria. At this step, we excluded 1141 articles, leaving a total of 288 papers for a full-text screen. After reading the full texts of these 288 articles, 56 articles were found that met the selection criteria. Figure 1 provides a flowchart of the identification and selection of eligible studies.

Neuroimaging modalities

In this section, a detailed explanation of the most recent neuroimaging modalities used to predict the progression from MCI to AD dementia is provided. Furthermore, Table 1 reports an overview of the modalities used in the included articles as well as the number of studies that used each single modality or the combination of neuroimaging modalities.

MRI modalities

Out of all 56 identified articles, structural MRI was the most commonly used neuroimaging modality to predict the conversion from MCI to AD (48.2%). While only one study developed a multi-label prediction approach with both baseline sMRI and cerebrospinal fluid (CSF) data [20], five studies (8.9%) investigated the progression to AD among MCI patients by combining the structural neuroimaging with baseline neuropsychological assessments (NPA) (i.e. Mini-Mental State Exam (MMSE) [21]), Alzheimer's disease assessment score (ADAS), or logical memory immediate recall (LIMM) [16]). One




Fig. 1 Flowchart of the systematic review process

study evaluated the combination of three modalities (sMRI, CSF, and NPA) to identify patients with MCI who are most likely to progress to AD dementia within a relatively short period. It showed that there is a gradual improvement in the statistical measures across increasing biomarker combinations [22]. A single study added demographic information and genetic factors to the previous three modalities [23]. In this study, an integrative framework was developed that combined cross-sectional neuroimaging biomarkers measured by MRI such as hippocampal volume and entorhinal cortical thickness,

demographic information including age, sex, years of education and Apolipoprotein E (APOE) genotype at baseline with longitudinal CSF and cognitive performance biomarkers including composite scores for executive functioning (ADNI-EF) and memory (ADNI-MEM) [23]. A composite model including sMRI features, APOE genotype, neuropsychological assessments, and demographic information was assessed in two separate studies [24, 25]. Lastly, one study demonstrated the potential of using resting-state functional MRI (rs-fMRI) to classify MC converters-to-AD from non-converters with high

Table 1 Summary of modalities used in the prediction of conversion from MCI to AD dementia as well as the number of studies used each modality or the combination of modalities

| Neuroimaging Modality | Non- Neuroimaging Modality | Number of Studies | Ref |
|-----------------------|---|-------------------|---|
| sMRI | NA | 28 | [13], [37], [38], [39], [40], [41], [42], [6], [43], [44], [45], [46], [47], [48], [17], [9], [49], [50], [51], [52], [53], [54], [55], [56], [57], [58], [59]. |
| | CSF | 1 | [20] |
| | NPA | 5 | [21], [16], [60], [5], [61] |
| | CSF, NPA | 1 | [22] |
| | NPA, genetic, Demo | 2 | [24], [25] |
| | CSF, NPA, genetic, Demo | 1 | [23] |
| fMRI | Rs-fMRI | 1 | [11] |
| SPECT | NPA | 1 | [31] |
| EEG | Gen | 1 | [10] |
| PET | NA | 6 | [26], [27], [62], [8], [63], [64] |
| | NPA | 1 | [28] |
| | genetic, Demo | 1 | [29] |
| sMRI, PET | NA | 2 | [34], [15] |
| | NPA, Demo | 1 | [65] |
| | NPA, genetic, Demo | 1 | [66] |
| | CSF | 1 | [67] |
| | CSF, NPA | 1 | [35] |
| | CSF, NPA, genetic, Demo, Cognitive resilience | 1 | [7] |
| sMRI, fMRI | NA | 1 | [36] |

Abbreviation: CSF, Cerebrospinal Fluid; NPA, Neuropsychological Assessment; SPECT, Single Photon Emission Computed Tomography; sMRI, structural Magnetic Resonance Imaging; rs-fMRI, resting-state functional MRI; EEG, Electroencephalogram; PET, Positron Emission Tomography; Demo, Demographic information; NA, Not applicable

NOTE. NA: Non- Neuroimaging Modality was not used in these studies

accuracy by identifying affected brain regions underlying the conversion [11]. The majority of studies have been done with structural MRI scans. While these systems are known for providing high spatial resolution for neuroimaging data, they are immobile and require expensive ongoing maintenance. Several studies that combined MRI scans with neuropsychological assessments or demographic information and genetic factors showed the potential improvement of model performance.

PET modalities

Out of 56 studies, six research studies used PET in predicting the conversion to AD dementia in patients with MCI. Four out of these six studies assessed the capacity

of fluorodeoxyglucose PET (FDG-PET) in discriminating MCI patients who converted to AD from those who did not by capturing the early deterioration of brain glucose metabolism. One of these six studies showed that their proposed deep learning approach could accurately predict cognitive decline in MCI patients by combining information from FDG-PET and 18 F-florbetapir (AV-45) PET [26]. Another study explored both separate and combined values of brain glucose metabolism (FDG-PET) and cerebral amyloid burden (Pittsburgh Compound-B-PET) for the selection of subjects who would eventually convert to AD dementia [27]. Their findings showed that measures of brain glucose metabolism and amyloid load provide powerful information with complementary roles that could improve the global accuracy of AD conversion prediction [27]. The efficiency of combined neuropsychological assessments (ADAS-cog score), amyloid PET (florbetapir PET), and FDG PET modality over single modalities in the prediction of AD conversion was evaluated in only one study [28]. Finally, one study used amyloid PET imaging along with demographic information such as age, gender, and APOE genotype status to identify incipient AD dementia individuals using a machine learning-based probabilistic method [29].

EEG and SPECT modalities

EEG is a non-invasive and relatively low-cost procedure that has been widely used in a large number of studies focused on pathological brain aging [30]. However, our selection criteria as explained in Sect. 2.2 identified only a single study that, using EEG connectivity markers, investigated the conversion of prodromal MCI to AD [10]. Their experimental results indicated that EEG connectivity analysis, combined with APOE genotyping, represents a combination of biomarkers that reach high classification performance for those at high-risk of converting from MCI to [10].

Likewise, a single study was found that evaluated the ability to predict AD dementia by considering the baseline of Single Photon Emission Computed Tomography (SPECT) perfusion abnormalities along with long-term memory disorders [31]. Compared to FDG- PET, SPECT is relatively more accessible and cost-effective [32, 33]. The results confirmed that the association of neuropsychological (EMS) and brain perfusion SPECT could develop the accuracy in detecting subjects who will progress to AD dementia [31].

Neuroimaging multimodalities

The inclusion of additional biomarkers may improve the accuracy with which individuals at risk of converting from MCI to AD are identified. We identified seven studies (12.5%) that investigated the predictive power of combining multimodal information from sMRI and

PET images. Two of these studies only considered the combination of these neuroimaging data [15, 34], and the remaining five studies also added other non-neuroimaging biomarkers, including neuropsychological assessment, demographic information (i.e. gender, age), biomarkers from cerebrospinal fluid (CSF), genetic factors and cognitive resilience (i.e. the number of errors on the American National Adult Reading Test (ANART)). Some of these studies showed that the performance of classifying progressive-MCI from stable-MCI individuals using a combination of modalities was better than those built with a single modality [34, 35]. A study explored the integration of two types of MRI data; rs-fMRI and sMRI. Their findings also revealed that compared to a single modality approach, the integration of rs-fMRI and sMRI can improve the performance of identification of the early stage of AD [36].

Data analysis techniques

Conventional machine learning techniques

This section provides a systematic discussion of machine learning (ML) techniques applied to analyze the single/multimodal patient information in the process of transition from MCI to AD dementia. Table 2 illustrates different types of machine learning approaches with their validation system and performance including accuracy (ACC), sensitivity (SEN), and specificity (SPE) of predicting the incidence of AD along with neuroimaging modalities and extracted features.

As reported in Table 2, most ML methods used in the studies have a linear classification baseline. Regression is the simplest classification model, which assumes a linear relationship between the outcome variable and features. The evident disadvantages of regression are that it can miss nonlinear relationships between variables and that it is very sensitive to outliers. However, the major advantages of regression are the simplicity of its assumptions, its applicability to small datasets, and relatively high interpretability of results [68].

Table 2 also shows that from a total of 56 selected studies, Support Vector Machines (SVM) was the most frequently used ML technique (43.8%). SVM is a notable expansion of regression in the sense of detecting outliers and making robust linear models. However, the major drawback of SVM is that it can miss nonlinear relationships between features and outcomes [14]. Some examples of other techniques that appeared less frequently in the reviewed studies include Random Forest (RF), Ensemble Multiple Kernel Learning and Bayesian Rule.

While the majority of studies have used cross-validation as the model evaluation technique, eight of the studies did not report their validation techniques and one study did not use any validation system. The lack of using any validation system does not ensure the generalizability

of their model to independent data that makes the reported evaluation unreliable.

The majority of the studies (80.3%, 45/56) used the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu) in their models. This calls into question the applicability of these models to the general population, as these models may be overfitted to this dataset. The remaining studies used databases that were implemented in different countries including China [54], Germany [22], Italy [10, 31], Sweden [27], Korea [62], Belgium [35], and Finland [8].

Deep learning techniques

Deep learning (DL) methods are a family of machine learning algorithms that are widely used in medical imaging due to their specific architecture [64]. Compared to conventional machine learning techniques that often have a "shallow" structure, deep learning methods are composed of several layers that integrate and abstract information at each layer [6]. Besides, in deep learning algorithms, feature learning and the discovery of informative representations from data are performed automatically [69]. As such, DL methods can easily handle complex nonlinear data without the requirement of the professional knowledge of experts in the field. However, they are usually dependent on large training data and can have very low interpretability [6].

The list of deep learning techniques, along with validation techniques, modalities, and neuroimaging features, are indicated in Table 3. This table shows that deep learning techniques were used in eight studies and consisted of Feed-Forward Neural Networks (NN) [9, 34, 64], recurrent Neural Networks (RNN) [23], Convolutional Neural Networks (CNN) [26, 37, 42], and a combination of CNN and RNN [6].

Feed-Forward NN is a multi-layer architecture where each layer consists of a group of neurons. A neuron can be imagined as logistic regression. The NN is capable of learning complex relationships by utilizing non-linear activation functions. One research group proposed a Multiscale Deep Neural Network (MDNN) to exploit the multiscale features [34]. They applied their algorithm independently on single FDG-PET, single sMRI images and the combination of both modalities. Their findings showed that the performance of their multiscale neural network built with the combination of FDG-PET and structural MRI image modalities yielded a higher classification performance compared to using either structural MRI or FDG-PET scans alone [34]. However, the drawback of this architecture was that it required a high number of parameters, making the training task challenging.

Another study used a multimodal RNN to study the longitudinal cerebrospinal fluid (CSF) and cognitive measurements that are integrated with cross-sectional MRI

Table 2 Summary of machine learning techniques in prediction of conversion from MCI to AD dementia

| Ref | Year | Modality | Data base | Neuroimaging Features | Method(s) | Conversion Time (months) | Sample Size | Validation System | Performance (%) | Remark |
|------|------|--|-------------------------|--|---|--|--------------------------------------|----------------------|--|--|
| [13] | 2017 | sMRI | ADNI | Textural features • Statistical features • Model based features • Image transforms Volumetric features • GM volume • WM volume • CSF volume | • Bayesian Rule • Majority Voting • RBF SVM | 0–12 | pMCI:30 sMCI:30 NC:30 AD:30 | Leave-one-out | ACC:100 SEN:100 SPE:100 | Bayesian Rule performed better than other classifiers. Feature selection: Gain ratio |
| [45] | 2017 | sMRI | ADNI | sMRI • GM volume • Cortical thickness • Surface area • Sulcal depth and curvature | SVM | 0–24 | pMCI:40 sMCI:46 NC:72 | Leave-one out | ACC:98.84 SEN:97.5 SPE:100 | Feature selection: L2-1 norm Regression |
| [22] | 2017 | • sMRI • CSF • NPA | Their database, Germany | Hippocampal volume | SVM | 0–36 | pMCI:28 sMCI:87 | No report | AUC:82 SEN:89 SPE:67 | - |
| [36] | 2018 | • sMRI • rs-fMRI | ADNI | sMRI • Volume of GM • Surface area • Cortical thickness • Curvature rs-fMRI • Local and global graph measures of brain connectivity | SVM | 0–36 | pMCI:18 sMCI:62 | 9-fold | ACC:96.97 SEN:94.97 SPE:100 | Integrated sMRI with rs-fMRI. |
| [35] | 2019 | • sMRI • Florbetapir-PET • FDG-PET • CSF • NPA | Memory Clinic, Belgium | sMRI • Hippocampal volumes • WM hyperintensities • Cortical GM Florbetapir-PET • Cortical SUVR FDG-PET • PCC SUVR | Linear Mixed-Effect Model | 0–12 | MCI:49 NC:13 AD:16 | independent test set | ACC:94 SEN:92 SPE:96 | - |
| [56] | 2017 | sMRI | ADNI | sMRI • Stationary velocity field • Jacobian determinant • Divergence • Deformation • Geodesic length | SVM | 0–36 | sMCI:43 pMCI:67 | 10-fold | ACC:92 SEN:95 SPE:90 | Dimensionality reduction: KPCA Feature selection: PCA |
| [10] | 2018 | • EEG • Genetic | Memory Clinic, Italy | EEG network small world properties of 7 frequency bands | Regression | $38.17 \pm 3.48^*$ $18.29 \pm 1.60^*$ | pMCI:71 sMCI:74 | 10-fold | ACC:91.7 SEN:96.7 SPE:86 | Feature selection: Kolmogorov-Smirnov test |
| [11] | 2017 | rs-fMRI | ADNI | Local and global measures of brain connectivity | SVM | 6–36 | pMCI:18 sMCI:62 | 9-fold | ACC:91.40 SEN:83.24 SPE:90.10 | Feature selection: MRMR |
| [31] | 2018 | • Brain perfusion SPECT • NPA | Their database, Italy | Mean activity of ROIs | Ensemble Multiple Kernel Learning | 0–24 | pMCI:15 sMCI:27 | No report | ACC:90 SEN:80 SPE:96 | Feature selection: F-Score |
| [16] | 2017 | • sMRI • NPA | ADNI | Five volumetric features | Majority Voting Regression | 0–36 | sMCI:13 pMCI:16 | Leave-one-out | ACC: 89.66 SEN: 87.50 SPE: 92.31 | Volume features included entorhinal, fusiform, hippocampus, middle temporal lobe and ventricles. |

Table 2 (continued)

| Ref | Year | Modality | Data base | Neuroimaging Features | Method(s) | Conversion Time (months) | Sample Size | Validation System | Performance (%) | Remark |
|------|------|---|------------------------------|--|---------------------|--------------------------|---|----------------------|--|--|
| [27] | 2017 | • FDG-PET • C-PiB-PET | Karolinska Institute, Sweden | FDG-PET • Manual labeling by visual inspection of AD positivity C-PiB-PET • SUVR score cut-off indicating amyloid positivity | Regression | 0-26.5 (median) | sMCI:16 pMCI:14 | No report | AUC: 96 | - |
| [51] | 2017 | sMRI | ADNI | Morphological features: • Whole-brain GM, WM • Subcortical structures • Cortical lobes | SVM | 0–36 | sMCI:132 pMCI:95 NC:135 AD:65 | 10-fold | ACC:88.99 SEN:86.32 SPE:90.91 | Considering the amygdala or hippocampus as ROI performed better than other features. |
| [8] | 2017 | FDG-PET | Their data-set, Finland | 13 meta-VOI-based FDG uptake in each hemisphere | SVM | 7.5 ± 1.5 (years) | pMCI:95 sMCI:27 NC:42 | 21-fold | ACC:88.5 SEN:87.4 SPE: 92.6 | SVM model used age-corrected baseline data. |
| [65] | 2017 | • FDG-PET • sMRI • NPA • Demo | SEAD-J | sMRI • z-score in medial temporal structures including entorhinal cortex, hippocampus, and amygdala FDG-PET • Visual inspection of PET images (predefined patterns) | Regression | 0–60 | sMCI:19 pMCI:49 | No report | ACC: 87.9 SEN: 89.8 SPE: 82.4 | Feature Selection: Stepwise |
| [24] | 2018 | • sMRI • NPA • Genetic • Demo | ADNI | • Hippocampal occupancy • Eight texture features | 3D Texture Analysis | 0–36 | pMCI:98 sMCI:106 NC:225 AD:183 | No report | SEN: 86.7 SPE: 83 | 3-D voxel-based texture analysis of MR images calculated texture features. |
| [66] | 2017 | • sMRI • FDG-PET • Genetic • Demo • NPA | ADNI | sMRI • GM volume • SUVR of several brain networks FDG-PET • SUVR of brain regions | Regression | 0–36 | pMCI:126 sMCI:108 AD: 121 NC:120 | Independent test set | ACC: 84.62 SEN: 86.51 SPE:82.41 | Feature Selection: ICA, Cox Proportional Hazard |
| [60] | 2018 | • sMRI • NPA | ADNI | • Volumes of brain regions • Surface area • Cortical thickness | Autoregressive SVM | 0–36 | pMCI 54 sMCI:65 | 5-fold | ACC: 84.29 SEN: 70.36 SPE: 92.31 | - |
| [29] | 2017 | • Florbeta-pir PET • Demo • Genetic | ADNI | Regional PET SUVR intensities | Random Forest | 0–24 | pMCI:43 sMCI:230 | Independent test set | ACC:84 SEN: 70.8 SPE: 86.5 | Feature Selection: Voxel-wise Logistic Regression |
| [61] | 2017 | • sMRI • NPA | ADNI | Voxel-wise MRI features | Random Forest | 0–36 | pMCI:171 sMCI:129 NC:229 AD: 191 | 10-fold | AUC:83.8 SEN:85.2 SPE:71.8 | Feature Selection: Elastic Net, LASSO |
| [5] | 2017 | • sMRI • NPA | ADNI | Fuzzy sets of hippocampal volume | SVM | 0–36 | pMCI:86 sMCI:71 NC:115 AD:96 | 10-fold | ACC:83.4 SEN:87.2 SPE:78.9 | Feature Selection: Kruskal-Wallis test |

Table 2 (continued)

| Ref | Year | Modality | Data base | Neuroimaging Features | Method(s) | Conversion Time (months) | Sample Size | Validation System | Performance (%) | Remark |
|------|------|---|--------------------------------|--|--|--------------------------|--|---|--------------------------------------|---|
| [7] | 2019 | •sMRI •FDG-PET •Florbetapir-PET •CSF •NPA •Cognitive resilience •Genetic •Demo | ADNI | sMRI • Hippocampal subfields volume • Cortical thickness FDG-PET • Degree of glucose metabolism in AD-specific ROIs F-florbetapir PET • Regional amyloid deposition assessed by SUVR | SVM, MKL, GLM | 0–36 | pMCI:39 sMCI:96 | 5-fold | ACC:81 SEN:93 SPE:77 | SVM performed better than other classifiers. Feature Selection: Mutual Information |
| [54] | 2019 | sMRI | XuanWu Hospital, China | Whole-brain WM structural networks/connectome | Kernelized SVM | 0–24 | pMCI:26 sMCI:26 NC:26 | Leave-one-out | ACC: 80.77 SEN:92.31 SPE:69.23 | Feature Selection: ANOVA, T-Test |
| [25] | 2017 | •sMRI •NPA •Demo •Genetic | ADNI | • Hippocampal volumetric integrity • Corpus callosum • Circularity | Random Forest | 0–6 | pMCI:162 sMCI:85 | 10-fold | ACC:80.2 SEN:79.6 SPE:81.2 | - |
| [44] | 2018 | sMRI | ADNI | • Voxel-based morphometry • Hippocampus volumes • Volumes of entorhinal cortex • Set of regional volumetric • Surface area • Cortical thickness | SVM, RLR | 0–36 | sMCI:100 pMCI:164 AD:200 NC:231 | Nested 10-fold | ACC:79.58 SEN:84.07 SPE:51.5 | Compared to RLR, SVM yielded lower specificity. Feature Selection: Elastic Net, PCA |
| [47] | 2017 | sMRI | ADNI | MRI Voxels at three levels (voxel, patch, and image level) | Hierarchical classification based on LRC | 0–48 | sMCI: 61 pMCI: 70 | Two nested CV loops (10-fold for each loop) | ACC: 79.4 SEN:86.5 SPE: 78.2 | Feature Selection: Regression |
| [62] | 2018 | FDG-PET | Seoul National Hospital, Korea | Degree of cerebral glucose metabolism in 6 ROIs | Regression | 0–24 | pMCI:19 sMCI:35 | No validation | AUC:79.4 SEN:76.47 SEP:75 | Both visual rating and computer-assisted analysis showed similar accuracy. |
| [17] | 2018 | sMRI | ADNI | • Structural volumes • Atrophy rates | SVM, Random Forest | 0–24 | pMCI:177 sMCI:166 | 6-fold | ACC: 79 SEN:82 SPE:74 | SVM and Random Forest performed similarly. |
| [21] | 2018 | •sMRI •PHS •NPA | ADNI | Volumetric features of ROIs | Linear Mixed-Effect Model | 0–36 | sMCI:154 pMCI:182 | No report | ACC: 78.9 SEN: 79.9 SPE: 77.8 | Feature Selection: Cox Proportional Hazards Model |
| [52] | 2018 | sMRI | ADNI | SBM texture measures of GM and WM | SVM | 6–12 | sMCI:64 pMCI:70 AD: 99 NC: 122 | 10-fold | ACC:77.6 SEN: 72.9 SPE: 82.6 | Feature Selection: Lasso, T-Test |

Table 2 (continued)

| Ref | Year | Modality | Data base | Neuroimaging Features | Method(s) | Conversion Time (months) | Sample Size | Validation System | Performance (%) | Remark |
|------|------|---------------------------------------|-----------------------------------|--|-----------------------------------|--------------------------|---|--------------------|--|---|
| [58] | 2018 | sMRI | ADNI + Their own data-base, China | Morphological features <ul style="list-style-type: none"> • Cortical thickness • Surface areas • GM volume • Sulcal depth • Metric distortion • Mean curvature | RBF SVM | 0–24 | pMCI:84 sMCI:86 NC:169 | Leave-one-out | ACC: 77.06 SEN: 77.91 SPE: 76.19 | Feature Selection: LASSO |
| [28] | 2018 | •FDG-PET •Florbeta-pir-PET •NPA | ADNI | Amyloid and metabolic SUVRs at voxel level and cortical ROIs | SVM | 37 ± 14 | pMCI:85 sMCI:204 NC:251 AD:144 | Leave-one-out | ACC:77 SEN:74 SPE:78 | Correlation between amyloid and metabolic SUVRs was assessed using Pearson's coefficient. |
| [20] | 2018 | • sMRI • CSF | ADNI | GM volume | SVM | 0–24 | pMCI:86 sMCI:106 NC: 112 AD: 109 | 10-fold | ACC: 76.3 SEN: 73.4 SPE: 78.6 | Feature Selection: Transfer Learning |
| [46] | 2018 | sMRI | ADNI | Hippocampus texture | SVM | No report | pMCI:165 sMCI:223 NC:226 AD:186 | Stratified 10-fold | AUC:76.1 SEN:74.9 SPE:70.2 | Feature Selection: Histogram |
| [38] | 2017 | sMRI | ADNI | Raw voxel value of regions with GM atrophy | SVM | 0–36 | pMCI:71 sMCI:65 NC:94 AD:92 | 10-fold | ACC:75 SEN:76.92 SPE:73.23 | Feature Selection: T-Test, Genetic Algorithm |
| [67] | 2017 | • sMRI • PET • CSF | ADNI | sMRI <ul style="list-style-type: none"> • Volume of GM tissue in 93 ROIs PET • Mean intensity of ROIs | SVM | 0–18 | pMCI:167 sMCI:226 NC:186 AD:226 | 10-fold | ACC:74.58 SEN:51.31 SPE:88.71 | Feature Selection: L2-1 norm Regularization |
| [53] | 2018 | sMRI | ADNI | Local surface roughness of hippocampus | Regression | 0–36 | pMCI:36 sMCI:61 | Nested | ACC:74.3 SEN:77.4 SPE:72.3 | Feature Selection: ANOVA |
| [50] | 2018 | sMRI | ADNI | ROI features & inter-regional features | Ensemble Multiple Kernel Learning | 0–18 | pMCI:120 sMCI:160 NC:230 AD:200 | 10-fold | ACC: 74.28 SEN:71.51 SPE: 76.46 | Feature Selection: F-Score |
| [15] | 2017 | • sMRI • PET | ADNI | sMRI <ul style="list-style-type: none"> • Average intensity of each ROI PET • GM tissue volumes in ROIs | SVM | 0–18 | pMCI:43 sMCI:56 NC:52 AD:51 | 10-fold | ACC: 72.4 SEN:49.1 SPE:94.6 | Feature Selection: L2-1 norm Regularization |
| [63] | 2018 | FDG-PET | ADNI | <ul style="list-style-type: none"> • Statistical features • Connectivity features • Graph-based features | Ensemble SVM | 0–24 | pMCI:44 sMCI:44 AD:94 NC:90 | Nested 10-fold | ACC: 72.33 SEN: 73.27 SPE:73.11 | Feature Selection: LASSO |
| [49] | 2018 | sMRI | ADNI | Texture features of the ROIs and spatial correlations | Multiple Kernel Learning | 0–18 | pMCI:120 sMCI:160 NC:230 AD:200 | 10-fold | ACC: 72.08 SEN: 75.11 SPE: 71.05 | Feature Selection: F-Score Feature Extraction: Whole brain hierarchical network |

Table 2 (continued)

| Ref | Year | Modality | Data base | Neuroimaging Features | Method(s) | Conversion Time (months) | Sample Size | Validation System | Performance (%) | Remark |
|------|------|----------|-----------|---|----------------------------------|--------------------------|--|-------------------------|--|--|
| [40] | 2017 | sMRI | ADNI | <ul style="list-style-type: none"> Cortical thickness Cortical surface area Cortical volume Sub-cortical volume both hemisphere SA volume Total intracranial volume | K-Nearest Neighbor | No report | pMCI:168 sMCI:229 NC:229 AD:192 | 10-fold stratified | ACC: 70.4 SEN: 67.7 SPE: 71.8 | Feature Selection: MFA, MKL |
| [43] | 2017 | sMRI | ADNI | <ul style="list-style-type: none"> Regional cortical thickness Subcortical volumes | Partial Least Squares Regression | 0–36 | pMCI:70 sMCI:75 NC:228 AD: 195 | No report | ACC: 68.3 SEN:80 SPE:57.3 | Age correction was added to improve the performance. |
| [48] | 2018 | sMRI | ADNI | CVRS measures including the scales of hippocampal atrophy, cortical atrophy, ventricular enlargement, and small vessel disease | Random Effect Model | 0–36 | sMCI:271 pMCI:69 | No report | AUC:67.7 SEN:63.8 SPE:65.7 | Feature Selection: Cox Proportional Hazards Mode |
| [59] | 2018 | sMRI | ADNI | Morphological features <ul style="list-style-type: none"> Cortical thickness Surface area Volume Local gyrification index Sulcal depth Gyrus height | SVM-RFE | 0–36 | MCI:221 NC:165 AD:142 | N-fold (N = 5,7,10) | ACC: 67.42 SEN: 72.22 SPE: 61.05 | Feature Selection: Recursive Feature Elimination, LASSO |
| [55] | 2018 | sMRI | ADNI | GM density | SVM | 0–18 | pMCI:76 sMCI:134 NC:162 AD:137 | 5-fold | ACC:65.4 SEN: 68.3 SPE: 64.2 | Feature Selection: LASSO |
| [57] | 2019 | sMRI | ADNI | Cortical thickness of brain regions | SVM | 0–36 | pMCI:126 sMCI:95 NC:165 AD:142 | 10-fold | ACC: 63.69 SEN: 78.56 SPE: 45.39 | Feature Selection: Manifold Regularization, L2-1 norm Regularization |
| [41] | 2017 | sMRI | ADNI | Voxel-wise tissue probability maps of WM, GM, and CSF | MARS Regression | 0–18 | pMCI:176 sMCI:134 NC:162 AD:136 | 3-times repeated k-fold | SEN: 62.16 SPE:59.70 | Feature Selection: Generalized Linear Model, SVM, L2-1 Norm |
| [39] | 2017 | sMRI | J-ADNI | Connectivity matrix of GM | SVM | 6–36 | pMCI:45 sMCI:42 NC:61 AD:83 | 10-fold | ACC:61.05 SEN:52.65 SPE:70.52 | Feature Selection: Histogram |

Abbreviations: CSF, Cerebrospinal Fluid; NPA, Neuropsychological Assessment; SPECT, Single Photon Emission Computed Tomography; sMRI, structural Magnetic Resonance Imaging; rs-fMRI, resting-state functional MRI; EEG, Electroencephalogram; PET, Positron Emission Tomography; C-PIB-PET, C-labelled Pittsburgh Compound-B- Positron Emission Tomography; Demo, Demographic information; RBF, Radial Basis Function; J-ADNI, Japanese-Alzheimer's Disease Neuroimaging Initiative; MFA, Marginal Fisher Analysis; MKL, Multiple Kernel learning; GLM, Generalized Linear Models; MARS, Multivariate Adaptive Regression Splines; RLR, Regularized Logistic Regression; SUVR, Standardized Uptake Value Ratio; Random under sampling Random Forest; ROI, Regions of Interest; ADNI, Alzheimer's Disease Neuroimaging Initiative; pMCI, progressive Mild Cognitive Impairment; sMCI, stable Mild Cognitive Impairment; GM, Grey Matter; WM, White Matter; SEAD-J, Studies on Diagnosis of Early Alzheimer's Disease-Japan; SBM, Spherical Brain Mapping; MRMR, Multivariate Minimal Redundancy Maximal Relevance; KPCA, Kernel Principle component Analysis; LASSO, Least Absolute Shrinkage and Selection Operator; CV, Cross Validation; PCC, Posterior Cingulate Cortex; STD, Standard Deviation; RFE, Recursive Feature Elimination

NOTE. Modality: the type of modality in each study. Neuroimaging Features: neuroimaging features in each study. Conversion Time: the time range for conversion from MCI to AD dementia. Performance: performance of classifying sMCI vs. pMCI in terms of accuracy (ACC), sensitivity (SEN), specificity (SPE), and area under the curve (AUC) when available

NOTE. Several studies focused on the discrimination of pMCI from sMCI as well as binary (i.e., AD vs. NC) or multiclass classification (i.e., AD vs. MCI vs. NC). In this study, we only focused on the classification of pMCI from sMCI and the performance section indicates the best results for this type of classification

*Months of follow-up for sMCI and pMCI groups were 38.17 ± 3.48 and 18.29 ± 1.60 , respectively

Table 3 Summary of deep learning techniques in prediction of conversion from MCI to AD dementia

| Ref | Year | Modality | Data base | Neuroimaging Features | Conversion Time (months) | Sample size | Method/ Network Structure | Validation System | Performance (%) | Remark |
|------|------|--|-----------|--|--------------------------|---|---------------------------|-------------------|--|--|
| [26] | 2018 | •FDG PET •AV-45 PET | ADNI | CNN feature map obtained from the PET images | 0–36 | pMCI:79 sMCI:92 NC:182 AD:139 | CNN | 10-fold | ACC:84.2 SEN:81 SPE:87 | Deep CNN was trained using 3-D PET volumes of AD and NC as inputs to discriminate between sMCI and pMCI. |
| [34] | 2018 | •FDG-PET •sMRI | ADNI | sMRI •Patch-based volume FDG-PET •Patch-based mean intensity | 0–36 | pMCI:217 sMCI:409 NC:378 AD:238 | Multiscale Multimodal DNN | 10-fold | ACC: 82.93 SEN:79.69 SPE: 83.84 | - |
| [64] | 2018 | FDG-PET | ADNI | Patch-based mean intensity | 0–36 | pMCI:112 sMCI:409 NC:304 AD:226 | Multiscale DNN | 10-fold | ACC: 82.51 SEN: 81.36 SPE: 82.85 | Ensemble multiple classifiers using different validation set made the network more robust and stable. |
| [9] | 2018 | sMRI | ADNI | •Morphology of Hippocampus •Cortical volume •Surface area •Cortical thickness | 0–36 | pMCI:164 sMCI:100 NC: 229 AD:188 | CNN | leave-one-out | ACC: 81.4 SEN: 89.6 SPE:68 | - |
| [23] | 2019 | •sMRI •Demo •Genetic •NPA •CSF | ADNI | •Hippocampal volume •Entorhinal cortical thickness | 0–24 | pMCI:134 sMCI:561 | RNN | 5-fold | ACC: 81 SEN:84 SPE:80 | - |
| [42] | 2018 | sMRI | ADNI | Local visual and global shape features of hippocampus | No report | pMCI:165 sMCI:231 NC: 223 AD:192 | CNN | 5-fold | ACC:75 SEN:73.33 SPE:76.19 | Combined the global and local features of the hippocampus by 3D Densely CNN and shape analysis. |

Table 3 (continued)

| Ref | Year | Modality | Data base | Neuroimaging Features | Conversion Time (months) | Sample size | Method/ Network Structure | Validation System | Performance (%) | Remark |
|------|------|----------|-----------------------------|--------------------------------------|--------------------------|--|---------------------------|-------------------|-------------------------------------|--|
| [37] | 2019 | sMRI | ADNI + Milan dataset, Italy | CNN feature map obtained from MRI | 0–36 | •ADNI pMCI:253 sMCI:510 NC:352 AD:294 •Milan pMCI:27 sMCI:23 NC:55 AD:124 | CNN | 10-fold | ACC:74.8 SEN:75.8 SPE:74.1 | - |
| [6] | 2019 | sMRI | ADNI | Spatial features from GM density map | 0–36 | pMCI:167 sMCI:236 NC:229 AD:198 | CNN + RNN | 5-fold | ACC:71.71 SEN:65.27 SPE:76.27 | CNN learned the spatial features of MR images and then, RNN was constructed on the outputs of CNN. |

Abbreviations: CSF, Cerebrospinal Fluid; NPA, Neuropsychological Assessment; Tomography; sMRI, structural Magnetic Resonance Imaging; PET, Positron Emission Tomography; Demo, Demographic information; ADNI, Alzheimer's Disease Neuroimaging Initiative; pMCI, progressive Mild Cognitive Impairment; sMCI, stable Mild Cognitive Impairment; CNN, Convolutional Neural Networks; RNN, Recurrent Neural Networks; DNN, Deep Neural Network; VOIs, Volume of Interests; MLP, Multi-Layer Perceptron

NOTE. Modality: the type of modality in each study. Neuroimaging Features: Neuroimaging features in each study. Conversion Time: the time range for conversion from MCI to AD dementia. Performance: performance of classifying sMCI vs. pMCI in terms of accuracy (ACC), sensitivity (SEN), and specificity (SPE)

* The sMCI group remained as MCI throughout the ADNI study at the time of preparation of that manuscript (median follow-up time of 3 years) and the pMCI group progressed to AD with the median time to conversion of 1 year

biomarkers. An RNN has feedback loops on the hidden neurons, which can capture sequential information and share parameters across different time points. In this study, the architecture of their designed RNN allowed them to achieve a high prediction accuracy by incorporating longitudinal multi-domain data. However, their approach was limited by the small number of subjects as they needed to have all the required modalities at all time points [23].

A Convolutional neural network was used in three studies. In CNN, the building blocks are sets of filters that can be used to extract both local and high-level features from the input using convolution operation. Features are learned based on a hierarchical framework, starting with simple features such as edges and shapes, and going through more complex and detailed patterns at later stages of the network [70]. In the reviewed studies, this characteristic of CNN helped them in capturing the spatial relations between image pixels, resulting in higher performance. For example, in one study the designed CNN algorithm was robust to the variability of imaging protocols and qualities [37] and their results showed the feasibility of deep learning to capture the full spectrum of heterogeneity among data. This provided a less dataset-specific approach for developing a highly accurate predictive model.

In the last study, using the combination of convolutional and recurrent neural networks provided the

opportunity to learn both spatial and longitudinal features of structural MR images at multiple time points [6]. Their results showed promising performance for longitudinal analysis of AD prognosis using the combination of RNN and CNN methods.

Discussion

The present systematic review sought to describe and evaluate the capability of existing neuroimaging procedures to predict the likelihood of individuals converting from MCI to AD dementia. In the MCI stage, brain damages are relatively slight and potentially reversible. Being able to accurately predict the progression to AD at the early stage of MCI could open important new therapeutic opportunities to improve the health outcomes of those most at risk of the disease [71].

To obtain a clearer understanding of the state of this work, we turned first to reviewing the neuroimaging methods and data sources currently being used to capture brain-based data as individuals progress through the pathway of MCI to AD. In terms of imaging modalities, the vast majority of recent work has been done with structural MRI and PET scans. While known for providing high spatial resolution for neuroimaging data, these systems are expensive, immobile and require ongoing maintenance. As a consequence, even if accurate prediction tools are developed using these modalities, they may see only limited use and applicability in screening those

at risk for developing AD. By comparison, EEG is non-invasive, affordable and easy to implement the procedure. In real-world settings, where logistics and cost are important considerations, EEG may be a more desirable modality for screening MCI individuals. For example, low-cost EEG systems could allow more frequent testing to identify the progression of MCI over time. Unfortunately, our review identified only a single study that used this modality to study the progression of MCI to AD, and despite the highly accurate preliminary performance, there is clearly more work that needs to be conducted in this space [10, 72, 73]. The driving factor of this unbalanced reality is the fact that almost no longitudinal EEG datasets of MCI patients are available of MCI patients, whereas several longitudinal MRI datasets are currently available. We will turn to the consequences of this shortly but given the anticipated large increase in the rate of AD over the coming decade, there is likely insufficient time to conduct a new longitudinal study using EEG or another lower-cost neuroimaging modality. Nevertheless, we must stress that this remains a significantly under-developed field.

Our review also identified a noteworthy number of recent studies that combined MRI and/or PET scans with additional health data, such as neuropsychological assessments and genetic information [36, 37, 64]. Generally, these multi-modal studies led to better predictive accuracy, which would be expected given the complementary data captured by these different techniques. As before, however, the practical considerations of these multi-modal approaches bear considering: a practical diagnostic solution becomes more difficult—and arguably less useful—as more data collection modalities are added. In the worst case, the necessary data might not be available and possible in practical settings [8]. Although the use of multiple modalities may be warranted at present in order to improve the accuracy of predictive models, we also encourage researchers to consider the practical implementation of these models in real-world use settings.

Continuing from this, our review identified a concerning trend with respect to the data being used to build these predictive models. The vast majority of the studies we reviewed (80.3%) used the Alzheimer's Disease Neuroimaging Initiative (ADNI) database to study the progression from MCI to AD. Although this decision is understandable, given the volume and generally high quality of the data in this dataset, it has several limitations. First, in the ADNI database, most participants were recruited from memory clinics and advertisements, and MCI inclusion criteria were highly selective and the data was not sufficiently representative of the overall population [21]. Second, the ADNI is a multicenter study that has multiple acquisition protocols regarding the selection of patients, demographic characteristics, and diagnostic

procedures. This results in systematic confounding effects and low statistical power, neither of which can be completely controlled for at the analytic level [8]. Lastly, the grouping criteria defined in the ADNI database are not perfect and contain false-categorized cases, and the study dropouts are biased toward high-risk individuals, all of which can lead to a bias in the estimates of progression rates. Thus, any models derived from this dataset will likely require subsequent validation studies before they can be used to predict the conversion of MCI to AD from the general public.

Furthermore, our review showed that most studies tracked the conversion from MCI to AD over a relatively short time frame ranging from about 6 to 36 months. Only a few studies had a longer follow-up duration. This relatively short follow-up period means that some of the individuals who were classified as stable MCI will in fact have progressed to AD dementia, or to some other neurodegenerative disease, beyond this tracking period. Therefore, the ground truth of clinically diagnosed sMCI patients might be inaccurate in ways that are difficult to quantify. Future studies should consider using databases with longer clinical follow-ups in order to exclude patients who do develop pMCI in the future.

As the data analysis algorithms used on these neuroimaging data are also critically important, this review also investigated the analysis approaches currently being used in the field as well.

Most studies used simple linear methods such as SVM and regression as their classification techniques. A justification for the prevalent use of linear methods over more sophisticated classification techniques is their simplicity, making them the first choice for such classification tasks. Additionally, the consistency of classifiers across different studies leaves the door open for direct comparison of other design decisions involved such as feature selection and preprocessing. However, these methods have well-studied limitations in their ability to accurately identify non-linear relationships between variables [74]. As non-linearities are relatively common in health data, we recommended that future studies turn to more advanced classification techniques that do not miss the nonlinear relationships between features and outcomes.

Deep learning algorithms are a family of ML methods that can learn hidden information from high-dimensional neuroimaging data. However, the main challenge of the deep learning methods used in the reviewed studies is that they rely on multiple layers of data processing with many parameters involved, and therefore require a large number of samples for training and tuning parameters. Particularly, this is a major issue in AD prediction, where the number of samples in the datasets available is limited [26].

ML methods can be categorized into those in which the feature selection is embedded with classifier construction, such as most DNNs [37], and those which usually use features transformed or features selected from original variables, such as Kernel-based SVMs [57]. Most of the reviewed methods required the features to be extracted from the image in a separate feature selection task before classification [75]. It is recommended that future studies consider using embedded models, such as CNNs, that allow the raw voxels to be fed into the network as the input. In fact, providing the neural network with raw data enables the network to learn the important features that could have been discarded during the feature selection. However, researchers should take into account that providing the network with raw data results in a higher computational cost due to the higher dimensionality of the inputs and also the extra tasks introduced for the feature extraction. Furthermore, in cases where valuable hand-engineered features can be defined based on domain knowledge, this approach may not be desirable because those valuable features and information provided by the experts will be missed.

In the reviewed studies, two major cross-validation techniques were used to evaluate accuracy: Leave-one-out cross-validation and 10-fold cross-validation. In the leave-one-out approach, one sample is retained from the method at each iteration and is used for testing; the rest of the samples are given to the method as training data. The process is repeated until all samples have been used for testing. In the 10-fold approach, samples are randomly partitioned into 10 groups of equal size; at each iteration, one group is used for testing and the remaining groups as training data. The process is likewise repeated until all groups have been used for testing. Both cross-validation methods are imperfect. On the one hand, 10-fold cross-validation carries additional computational cost over leave-one-out cross-validation and retains 10% of the available data from the method, which results in a potential underestimation of accuracy achievable by the method. On the other hand, leave-one-out cross-validation has a higher variance than 10-fold cross-validation with respect to the dataset. These two techniques are usually used because of their simplicity and the standardization of the test in comparing different methods. We encourage future works to use other classification methods with significant advantages over these two techniques, including nested cross-validations, bootstraps, holdout, and permutation tests. It should also be noted that some studies did not report their cross-validation approach, and presumably reported accuracy on their training set, which makes their reported evaluation unreliable.

In the present review, the performance of studies in terms of accuracy, sensitivity, and specificity are also

represented. Although results are promising, these three measures can be limited in different ways by the data analysis technique being used. For example, several data analysis techniques are sensitive to feature selection and the tuning of many involved parameters. This problem is exacerbated where multiple layers of data processing algorithms are performed independently, and hence, the models and parameters cannot be jointly optimized. Furthermore, some of the discussed methods, such as deep learning models, are black-box models, meaning that it is difficult to understand why and how they make their decisions. This leads to limitations in the interpretability of the results. For example, it is difficult to infer which features and to what extent are contributing to the decision made by the classifier in deep learning models. In future research, these limitations should be addressed in order to develop more reliable predictive models that can be used in routine clinical settings.

It should be noted that most of the studies are conducted by researchers in the field of computer science and they have focused on developing their data analysis algorithms using commonly used types of modalities and features. Thus, in most of these studies, a systematic search to find the appropriate modalities and feature(s) is ignored. In the future, more collaboration among researchers in the field of computer science, neuroscience and cognitive science would assist to overcome the challenges and achieve a desirable performance by merging these domains.

There are a few limitations to the current systematic review. One limitation is that, due to differences in datasets, length of follow-up, type of modalities, prediction models, sample sizes and validation methods, it was not feasible to quantitatively compare the performances of the reviewed studies and determine the “best” approach for predicting the conversion likelihood from MCI to AD. Another limitation was the lack of detailed reports of features, validation methods, data analysis techniques, and data sources in some of the MCI conversion studies. However, we provided a comprehensive review of the strengths and drawbacks of neuroimaging modalities and data analysis techniques used in the reviewed studies along with concrete recommendations for future studies.

Conclusion

A systematic review of neuroimaging procedures for the prediction of transition from MCI to AD dementia was conducted to describe their neuroimaging modalities and features as well as associated machine learning techniques in the most recent studies. With respect to data modality methods, the vast majority of current studies are using MRI data from the ADNI dataset. As a result, the field is at risk of developing models with reproducibility with the general public, and which may lead to

methods that are too cost-prohibitive and logistically challenging to be of broad use. With respect to data analysis methods, deep learning approaches for analyzing brain scans could achieve high performance. There are major concerns regarding the use of nonrepresentative participants, clinical follow-ups, standardization of protocols and technical elements of diagnostic tests, and dealing with dropouts. The finding of studies would be more valuable if the larger sample size and longer conversion period could be considered. These issues need to be resolved before predictive models can be deployed in healthcare settings for the identification of individuals at risk of progressing from MCI to Alzheimer's disease.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12883-023-03323-2>.

Supplementary Material 1

Acknowledgements

The authors kindly thank Isaac G. Morgan for his help in initial data extraction.

Authors' contributions

The study was conceived by MA. MA, GJC, TDC, and SM designed the research question and conceptualized the study. MA and KRW prepared and performed the systematic search; MA and KRW did the title/abstract and full-text reviews; MA, AA, MM extracted the data and did the analysis; MA extracted all data, each AA and MM extracted half of the data, independently. MA, SD and all authors provided input into the design, edited and revised the manuscript. All authors read and approved the final manuscript. MA is the guarantor of the review. All authors report no conflicts of interest or financial disclosures.

Funding

This work was supported by funding from the AGE-WELL, Canada's technology, and the aging network. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Data Availability

Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Received: 3 August 2022 / Accepted: 8 July 2023

Published online: 22 August 2023

References

1. Reiman EM, Quiroz YT, Fleisher AS, Chen K, Velez-Pardo C, Jimenez-Del-Rio M, et al. Brain imaging and fluid biomarker analysis in young adults at genetic

- risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study. *Lancet Neurol*. 2012;11(12):1048–56.
2. Alzheimer's A. 2019 Alzheimer's disease facts and figures. *Alzheimer's & Dementia*. 2019;15(3):321–87.
3. Li K, O'Brien R, Lutz M, Luo S. A prognostic model of Alzheimer's disease relying on multiple longitudinal measures and time-to-event data. *Alzheimer's & Dementia*. 2018;14(5):644–51.
4. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimer's & Dementia*. 2011;7(3):270–9.
5. Tangaro S, Fanizzi A, Amoroso N, Bellotti R. A fuzzy-based system reveals Alzheimer's Disease onset in subjects with mild cognitive impairment. *Physica Med*. 2017;38:36–44.
6. Cui R, Liu M. RNN-based longitudinal analysis for diagnosis of Alzheimer's disease. *Comput Med Imaging Graph*. 2019;73:1–10.
7. Varatharajah Y, Ramanan VK, Iyer R, Vemuri P. Predicting Short-term MCI-to-AD Progression Using Imaging, CSF, Genetic Factors, Cognitive Resilience, and Demographics. *Scientific Reports*. 2019;9(1). <http://www.nature.com/articles/s41598-019-38793-3>.
8. Pagani M, Nobili F, Morbelli S, Arnaldi D, Giuliani A, Öberg J, et al. Early identification of MCI converting to AD: a FDG PET study. *Eur J Nucl Med Mol Imaging*. 2017;44(12):2042–52.
9. Lin W, Tong T, Gao Q, Guo D, Du X, Yang Y et al. Convolutional Neural Networks-Based MRI Image Analysis for the Alzheimer's Disease Prediction From Mild Cognitive Impairment. *Front Neurosci*. 2018;12. <https://doi.org/10.3389/fnins.2018.00777>.
10. Vecchio F, Miraglia F, Iberite F, Lacidogna G, Guglielmi V, Marra C et al. Sustainable method for Alzheimer dementia prediction in mild cognitive impairment: electroencephalographic connectivity and graph theory combined with apolipoprotein E: MCI Conversion. *Annals of Neurology*. 2018;84(2):302–14.
11. Hojjati SH, Ebrahimzadeh A, Khazaei A, Babajani-Feremi A. Predicting conversion from MCI to AD using resting-state fMRI, graph theoretical approach and SVM. *J Neurosci Methods*. 2017;282:69–80.
12. Jack CR, Holtzman DM. Biomarker modeling of Alzheimer's Disease. *Neuron*. 2013;80(6):1347–58.
13. Ayub A, Farhan S, Fahiem MA, Tauseef H. A Novel Approach for the prediction of Conversion from mild cognitive impairment to Alzheimer's disease using MRI images. *Adv Electr Comput Eng*. 2017;17(2):113–22.
14. Ceamanos X, Waske B, Benediktsson JA, Chanussot J, Fauvel M, Sveinsson JR. A classifier ensemble based on fusion of support vector machines for classifying hyperspectral data. *Int J Image Data Fusion*. 2010;1(4):293–307.
15. Zhu X, Suk HI, Wang L, Lee SW, Shen D. A novel relational regularization feature selection method for joint regression and classification in AD diagnosis. *Med Image Anal*. 2017;38:205–14.
16. Minhas S, Khanum A, Riaz F, Alvi A, Khan SA. A Nonparametric Approach for mild cognitive impairment to AD Conversion Prediction: results on Longitudinal Data. *IEEE J Biomedical Health Inf*. 2017;21(5):1403–10.
17. Ledig C, Schuh A, Guerrero R, Heckemann RA, Rueckert D. Structural brain imaging in Alzheimer's disease and mild cognitive impairment: biomarker analysis and shared morphometry database. *Scientific Reports* 2018;8(1). <https://www.nature.com/articles/s41598-018-29295-9>.
18. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Systematic Reviews*. 2015;4(1). <https://systematicreviewsjournal.biomedcentral.com/articles/https://doi.org/10.1186/2046-4053-4-1>.
19. Ahmadzadeh M, Christie GJ, Cosco TD, Moreno S. Neuroimaging and analytical methods for studying the pathways from mild cognitive impairment to Alzheimer's disease: protocol for a rapid systematic review. *Systematic Reviews*. 2020;9(1). <https://systematicreviewsjournal.biomedcentral.com/articles/https://doi.org/10.1186/s13643-020-01332-7>.
20. Cheng B, Liu M, Zhang D, Shen D. Robust multi-label transfer feature learning for early diagnosis of Alzheimer's disease. *Brain Imaging and Behavior*. 2019;13(1):138–53.
21. Kauppi K, Fan CC, McEvoy LK, Holland D, Tan CH, Chen CH et al. Combining Polygenic Hazard Score With Volumetric MRI and Cognitive Measures Improves Prediction of Progression From Mild Cognitive Impairment to Alzheimer's Disease. *Frontiers in Neuroscience*. 2018;12. <https://doi.org/10.3389/fnins.2018.00260>.

22. Frölich L, Peters O, Lewczuk P, Gruber O, Teipel SJ, Gertz HJ et al. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia. *Alzheimer's Research & Therapy*. 2017;9(1). Available from: <http://alzres.biomedcentral.com/articles/https://doi.org/10.1186/s13195-017-0301-7>.
23. Lee G, Nho K, Kang B, Sohn KA, Kim D. Predicting Alzheimer's disease progression using multi-modal deep learning approach. *Scientific Reports*. 2019;9(1). <http://www.nature.com/articles/s41598-018-37769-z>.
24. Luk CC, Ishaque A, Khan M, Ta D, Chenji S, Yang YH et al. Alzheimer's disease: 3-Dimensional MRI texture for prediction of conversion from mild cognitive impairment. *Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring*. 2018;10:755–63.
25. Mubeen AM, Asaei A, Bachman AH, Sidtis JJ, Ardekani BA. A six-month longitudinal evaluation significantly improves accuracy of predicting incipient Alzheimer's disease in mild cognitive impairment. *J Neuroradiol*. 2017;44(6):381–7.
26. Choi H, Jin KH. Predicting cognitive decline with deep learning of brain metabolism and amyloid imaging. *Behav Brain Res*. 2018;344:103–9.
27. Iaccarino L, Chiotis K, Alongi P, Almkvist O, Wall A, Cerami C et al. A cross-validation of FDG- and Amyloid-PET biomarkers in mild cognitive impairment for the risk prediction to Dementia due to Alzheimer's Disease in a clinical setting. *J Alzheimer's Disease*. 2017;59(2):603–14.
28. Ben Bouallègue F, Mariano-Goulart D, Payoux P. Joint Assessment of Quantitative 18F-Florbetapir and 18F-FDG Regional Uptake Using Baseline Data from the ADNI. Ardekani B, editor. *Journal of Alzheimer's Disease*. 2018;62(1):399–408.
29. Mathotaarachchi S, Pascoal TA, Shin M, Benedet AL, Kang MS, Beaudry T, et al. Identifying incipient dementia individuals using machine learning and amyloid imaging. *Neurobiol Aging*. 2017;59:80–90.
30. Morrison C, Rabipour S, Knoefel F, Sheppard C, Taler V. Auditory event-related potentials in mild cognitive impairment and Alzheimer's Disease. *CAR*. 2018;11(8):702–15.
31. Quaranta D, Gainotti G, Di Giuda D, Vita MG, Cocciolillo F, Lacidogna G, et al. Predicting progression of amnesic MCI: the integration of episodic memory impairment with perfusion SPECT. *Psychiatry Research: Neuroimaging*. 2018;271:43–9.
32. Sánchez-Catasús CA, Stormezan GN, van Laar PJ, Deyn PPD, Sánchez MA, Dierckx AJO. FDG-PET for prediction of AD dementia in mild cognitive impairment. A review of the state of the art with Particular emphasis on the comparison with other Neuroimaging Modalities (MRI and perfusion SPECT). *Curr Alzheimer Res*. 2017;14:127–42.
33. Valotassiou V, Malamitsi J, Papatriantafyllou J, Dardiotis E, Tsougos I, Psimadas D, et al. SPECT and PET imaging in Alzheimer's disease. *Ann Nucl Med*. 2018;32(9):583–93.
34. Lu D, Popuri K, Ding GW, Balachandrar B, Reg MF, Multimodal. and Multiscale Deep Neural Networks for the Early Diagnosis of Alzheimer's Disease using structural MR and FDG-PET images. *Scientific Reports*. 2018;8(1). <https://doi.org/10.3389/fnhum.2018.00204>.
35. Ottroy J, Niemantsverdriet E, Verhaeghe J, De Roock E, Struys H, Somers C, et al. Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and 18F-FDG-PET imaging. *NeuroImage: Clin*. 2019;22:101771.
36. Hojjati SH, Ebrahimzadeh A, Khazaei A, Babajani-Feremi A. Predicting conversion from MCI to AD by integrating rs-fMRI and structural MRI. *Computers in Biology and Medicine*. 2018;102:30–9.
37. Basaia S, Agosta F, Wagner L, Canu E, Magnani G, Santangelo R, et al. Automated classification of Alzheimer's disease and mild cognitive impairment using a single MRI and deep neural networks. *NeuroImage: Clin*. 2019;21:101645.
38. Beheshti I, Demirel H, Matsuda H. Classification of Alzheimer's disease and prediction of mild cognitive impairment-to-Alzheimer's conversion from structural magnetic resource imaging using feature ranking and a genetic algorithm. *Comput Biol Med*. 2017;83:109–19.
39. Beheshti I, Maikusa N, Daneshmand M, Matsuda H, Demirel H, Anbarjafari G. Classification of Alzheimer's disease and prediction of mild cognitive impairment Conversion using Histogram-Based analysis of patient-specific anatomical brain connectivity networks. *J Alzheimer's Disease* 2017 Aug 29;60(1):295–304.
40. Cao P, Liu X, Yang J, Zhao D, Huang M, Zhang J, et al. Nonlinearity-aware based dimensionality reduction and over-sampling for AD/MCI classification from MRI measures. *Comput Biol Med*. 2017;91:21–37.
41. Çevik A, Weber GW, Eyüboğlu BM, Oğuz KK. Voxel-MARS: a method for early detection of Alzheimer's disease by classification of structural brain MRI. *Ann Oper Res*. 2017;258(1):31–57.
42. Cui R, Liu M. Hippocampus Analysis by Combination of 3-D DenseNet and shapes for Alzheimer's Disease diagnosis. *IEEE J Biomedical Health Inf*. 2019;23(5):2099–107.
43. Falahati F, Ferreira D, Muehlboeck JS, Eriksdotter M, Simmons A, Wahlund LO, et al. Monitoring disease progression in mild cognitive impairment: Associations between atrophy patterns, cognition, APOE and amyloid. *NeuroImage: Clin*. 2017;16:418–28.
44. Gómez-Sancho M, Tohka J, Gómez-Verdejo V. Comparison of feature representations in MRI-based MCI-to-AD conversion prediction. *Magn Reson Imaging*. 2018;50:84–95.
45. Guo S, Lai C, Wu C, Cen G, The Alzheimer's Disease Neuroimaging Initiative. Conversion Discriminative Analysis on Mild Cognitive Impairment Using Multiple Cortical Features from MR Images. *Front Aging Neurosci*. 2017;9. <https://doi.org/10.3389/fnagi.2017.00146>.
46. Hett K, Ta VT, Manjón JV, Coupé P. Adaptive fusion of texture-based grading for Alzheimer's disease classification. *Comput Med Imaging Graph*. 2018;70:8–16.
47. Huang M, Yang W, Feng Q, Chen W. Longitudinal measurement and hierarchical classification framework for the prediction of Alzheimer's disease. *Scientific Reports*. 2017;7(1). <http://www.nature.com/articles/srep39880>.
48. Jang JW, Park JH, Kim S, Park YH, Pyun JM, Lim JS et al. A 'Comprehensive Visual Rating Scale' for predicting progression to dementia in patients with mild cognitive impairment. Reppermund S, editor. *PLOS ONE*. 2018;20;13(8):e0201852.
49. Liu J, Li M, Lan W, Wu FX, Pan Y, Wang J. Classification of Alzheimer's Disease Using Whole Brain Hierarchical Network. *IEEE/ACM Transactions on Computational Biology and Bioinformatics*. 2018;15(2):624–32.
50. Liu J, Wang J, Tang Z, Hu B, Wu FX, Pan Y. Improving Alzheimer's Disease Classification by Combining Multiple Measures. *IEEE/ACM Transactions on Computational Biology and Bioinformatics*. 2018;15(5):1649–59.
51. Long X, Chen L, Jiang C, Zhang L, Alzheimer's Disease Neuroimaging Initiative. Prediction and classification of Alzheimer disease based on quantification of MRI deformation. Chen K, editor. *PLOS ONE*. 2017;12(3):e0173372.
52. Martínez-Murcia FJ, Górriz JM, Ramírez J, Segovia F, Salas-Gonzalez D, Castillo-Barnes D et al. Assessing Mild Cognitive Impairment Progression using a Spherical Brain Mapping of Magnetic Resonance Imaging. *Journal of Alzheimer's Disease*. 2018;65(3):713–29.
53. Platero C, López ME, del Carmen Tobar M, Yus M, Maestu F. Discriminating Alzheimer's disease progression using a new hippocampal marker from T1-weighted MRI: The local surface roughness. *Human Brain Mapping*. 2019;40(5):1666–76.
54. Sun Y, Bi Q, Wang X, Hu X, Li H, Li X et al. Prediction of Conversion From Amnesic Mild Cognitive Impairment to Alzheimer's Disease Based on the Brain Structural Connectome. *Frontiers in Neurology*. 2019;9. <https://doi.org/10.3389/fnerv.2018.01178>.
55. Sun Z, Qiao Y, Lelieveldt BPF, Staring M. Integrating spatial-anatomical regularization and structure sparsity into SVM: improving interpretation of Alzheimer's disease classification. *NeuroImage*. 2018;178:445–60.
56. Sun Z, van de Giessen M, Lelieveldt BPF, Staring M. Detection of Conversion from Mild Cognitive Impairment to Alzheimer's Disease Using Longitudinal Brain MRI. *Front Neuroinform*. 2017;11. <https://doi.org/10.3389/fninf.2017.00016>.
57. Xu L, Yao Z, Li J, Lv C, Zhang H, Hu B. Sparse feature learning with label information for Alzheimer's Disease classification based on magnetic resonance imaging. *IEEE Access*. 2019;7:26157–67.
58. Yu K, Wang X, Li Q, Zhang X, Li X, Li S. Individual Morphological Brain Network Construction Based on Multivariate Euclidean Distances Between Brain Regions. *Frontiers in Human Neuroscience*. 2018;12. <https://doi.org/10.3389/fnhum.2018.00204>.
59. Zheng W, Yao Z, Xie Y, Fan J, Hu B. Identification of Alzheimer's disease and mild cognitive impairment using networks constructed based on multiple morphological brain features. *Biological Psychiatry: cognitive neuroscience and neuroimaging*. 2018;3(10):887–97.
60. Minhas S, Khanum A, Riaz F, Khan SA, Alvi A. Predicting Progression from mild cognitive impairment to Alzheimer's Disease using Autoregressive Modelling of Longitudinal and Multimodal biomarkers. *IEEE J Biomedical Health Inf*. 2018;22(3):818–25.

61. Tong T, Gao Q, Guerrero R, Ledig C, Chen L, Rueckert D, et al. A novel grading biomarker for the prediction of Conversion from mild cognitive impairment to Alzheimer's Disease. *IEEE Trans Biomed Eng.* 2017;64(1):155–65.
62. Kang JM, Lee JY, Kim YK, Sohn BK, Byun MS, Choi JE, et al. Visual rating and computer-assisted analysis of FDG PET in the prediction of Conversion to Alzheimer's disease in mild cognitive impairment. *Molecular Diagnosis & Therapy*; 2018;22(4):475–83.
63. Pan X, Adel M, Fossati C, Gaidon T, Guedj E. Multilevel feature representation of FDG-PET brain images for diagnosing Alzheimer's Disease. *IEEE J Biomedical Health Inf.* 2019;23(4):1499–506.
64. Lu D, Popuri K, Ding GW, Balachandar R, Beg MF. Multiscale deep neural network based analysis of FDG-PET images for the early diagnosis of Alzheimer's disease. *Med Image Anal.* 2018;46:26–34.
65. Study Group SEAD-J, Inui Y, Ito K, Kato T. Longer-term investigation of the value of 18F-FDG-PET and magnetic resonance imaging for Predicting the Conversion of mild cognitive impairment to Alzheimer's Disease: a Multi-center Study. *J Alzheimer's Disease.* 2017;60(3):877–87.
66. Liu K, Chen K, Yao L, Guo X. Prediction of Mild Cognitive Impairment Conversion Using a Combination of Independent Component Analysis and the Cox Model. *Front Hum Neurosci.* 2017;11. <https://doi.org/10.3389/fnhum.2017.00033>.
67. Lei B, Yang P, Wang T, Chen S, Ni D. Relational-regularized discriminative sparse learning for Alzheimer's Disease diagnosis. *IEEE Trans Cybernetics.* 2017;47(4):1102–13.
68. Dreiseitl S, Ohno-Machado L. Logistic regression and artificial neural network classification models: a methodology review. *J Biomed Inform.* 2002;35(5–6):352–9.
69. Zhang L, Wang M, Liu M, Zhang D. A Survey on Deep Learning for Neuroimaging-Based brain disorder analysis. *Front Neurosci.* 2020;8:14:779.
70. Wen J, Thibeau-Sutre E, Diaz-Melo M, Routier A, Bottani S, Dormont D et al. Convolutional Neural Networks for Classification of Alzheimer's Disease: Overview and Reproducible Evaluation.:68.
71. Christie GJ, Hamilton T, Manor BD, Farb NAS, Farzan F, Sixsmith A et al. Do Lifestyle Activities Protect Against Cognitive Decline in Aging? A Review. *Front Aging Neurosci.* 2017;9. <https://doi.org/10.3389/fnagi.2017.00381>.
72. Fraga FJ, Mamani GQ, Johns E, Tavares G, Falk TH, Phillips NA. Early diagnosis of mild cognitive impairment and Alzheimer's with event-related potentials and event-related desynchronization in N-back working memory tasks. *Computer methods and programs in Biomedicine.* 2018;164:1–13.
73. Mazaheri A, Segaert K, Olichney J, Yang JC, Niu YQ, Shapiro K, et al. EEG oscillations during word processing predict MCI conversion to Alzheimer's disease. *NeuroImage: Clin.* 2018;17:188–97.
74. Krakovska O, Christie G, Sixsmith A, Ester M, Moreno S. Performance comparison of linear and non-linear feature selection methods for the analysis of large survey datasets. *Fragkos KC, editor. PLOS ONE.* 2019;14(3):e0213584.
75. Kumar G, Bhatia PK. A Detailed Review of Feature Extraction in Image Processing Systems. In: 2014 Fourth International Conference on Advanced Computing & Communication Technologies. Rohtak, India: IEEE; 2014;5–12 <http://ieeexplore.ieee.org/document/6783417/>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.